Cheng Yi Pharmaceutical is determined to build a "big health product matrix" to serve the middle-aged and elderly population

Entering 2024, Cheng Yi Pharmaceutical's "Big Health Product Matrix" received more social attention. On the morning of January 5th, accompanied by leaders such as Zhang Zhenfeng, the Secretary of the Zhejiang Provincial Party Committee, Yi Lianhong, led a team to carry out a large-scale visit to the enterprise. After listening to the report of the enterprise leader, the provincial and municipal leaders believed that the company's developed super fish oil and other big health series products had good market prospects and encouraged "to grow and strengthen, build a century old store, and a market value of 100 billion".

To cope with the early arrival of the national aging population, Cheng Yi Pharmaceutical has established a "big health product matrix" that adapts to various health problems of middle-aged and elderly people. To prevent and treat osteoarthritis in the middle-aged and elderly population, the company's pure natural green aminoglycan product has steadily ranked among the top clinical sales in the country; To treat acute and chronic cholecystitis, biliary tract infections, gallbladder and biliary stones in patients of all ages, the company has launched the "Dan Yi Ning" tablet, which is an exclusive traditional Chinese medicine variety in the country; To solve the cardiovascular and cerebrovascular problems, especially hyperlipidemia, among the middle-aged and elderly population, the company has launched a series of ultra-high purity fish oil EPA soft capsules; In order to improve the immunity of the middle-aged and elderly population, the company has launched a series of nerve acid products; To solve the problem of sleep disorders in the middle-aged and elderly population, the company has launched a series of cicada flower cordyceps products. The matrix formed by the above products has been widely welcomed in the national market after being launched around 2023. The company has become the main enterprise in the life and health industry chain of Wenzhou City, and a "Cheng Yi sector" serving the health cause of the middle-aged and elderly population nationwide has entered the market.

On November 17th last year, the company established the "Cheng Yi Health Zhejiang Center" in the urban area of Wenzhou, becoming a bridge and link between enterprises and the market, and promoting successful experiences nationwide. At the end of December, Ruicheng Biomedical Technology Co., Ltd., a subsidiary of Cheng Yi Pharmaceutical, cooperated with Shanghai Ruijin Hospital to develop and treat pancreatic cancer, a patented product - "disposable negative pressure drainage kit", signed the first order of market supply, successfully realizing patent conversion. The subsidiary, Fujian Huakang Pharmaceutical Co., Ltd., has passed the national high-tech enterprise certification for the first time after obtaining the production approval for aminosugar raw materials. The Dendrobium officinale series products produced by Guangzhou Sandaoyuan Pharmaceutical Technology Co., Ltd., another subsidiary, are selling well in southern China. The three subsidiaries are expected to provide more and better big health products to the national market in 2024.

Article source: Volkswagen Securities Journal

Source link:http://m.dzzq.com.cn/bond/47181058.html